6 results on '"Caan, Matthan W A"'
Number of results to display per page
Search Results
2. Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment
- Author
-
Underwood, Jonathan, De Francesco, Davide, Cole, James H, Caan, Matthan W A, van Zoest, Rosan A, Schmand, Ben A, Sharp, David J, Sabin, Caroline A, Reiss, Peter, Winston, Alan Coolaboratori: Reiss P, Wit FWNM, Schouten J, Kooij KW, van Zoest RA, Elsenga BC, Janssen FR, Heidenrijk M, Zikkenheiner W, van der Valk M, Kootstra NA, Harskamp-Holwerda AM, Maurer I, Mangas Ruiz MM, Girigorie AF, Villaudy J, Frankin E, Pasternak A, Berkhout B, van der Kuyl T, Portegies P, Schmand BA, Geurtsen GJ, Ter Stege JA, Klein Twennaar M, Majoie CBLM, Caan MWA, Su T, Weijer K, Bisschop PHLT, Kalsbeek A, Wezel M, Visser I, Ruhé HG, Franceschi C, Garagnani P, Pirazzini C, Capri M, Dall'Olio F, Chiricolo M, Salvioli S, Hoeijmakers J, Pothof J, Prins M, Martens M, Moll S, Berkel J, Totté M, Kovalev S, Gisslén M, Fuchs D, Zetterberg H, Winston A, Underwood J, McDonald L, Stott M, Legg K, Lovell A, Erlwein O, Doyle N, Kingsley C, Sharp DJ, Leech R, Cole JH, Zaheri S, Hillebregt MMJ, Ruijs YMC, Benschop DP, Burger D, de Graaff-Teulen M, Guaraldi G, Bürkle A, Sindlinger T, Moreno-Villanueva M, Keller A, Sabin C, de Francesco D, Libert C, Dewaele S, Boffito M, Mallon P, Post F, Sachikonye M, Anderson J, Asboe D, Garvey L, Pozniak A, Vera J, Williams I, Campbell L, Yurdakul S, Okumu S, Pollard L, Otiko D, Phillips L, Laverick R, Fisher M, Clarke A, Bexley A, Richardson C, Macken A, Ghavani-Kia B, Maher J, Byrne M, Flaherty A, Mguni S, Clark R, Nevin-Dolan R, Pelluri S, Johnson M, Ngwu N, Hemat N, Jones M, Carroll A, Whitehouse A, Burgess L, Babalis D, Higgs C, Seah E, Fletcher S, Anthonipillai M, Moyes A, Deats K, Syed I, Matthews C., Underwood, Jonathan, De Francesco, Davide, Cole, James H, Caan, Matthan W A, van Zoest, Rosan A, Schmand, Ben A, Sharp, David J, Sabin, Caroline A, Reiss, Peter, Winston, Alan Coolaboratori: Reiss P, Wit FWNM, Schouten J, Kooij KW, van Zoest RA, Elsenga BC, Janssen FR, Heidenrijk M, Zikkenheiner W, van der Valk M, Kootstra NA, Harskamp-Holwerda AM, Maurer I, Mangas Ruiz MM, Girigorie AF, Villaudy J, Frankin E, Pasternak A, Berkhout B, van der Kuyl T, Portegies P, Schmand BA, Geurtsen GJ, Ter Stege JA, Klein Twennaar M, Majoie CBLM, Caan MWA, Su T, Weijer K, Bisschop PHLT, Kalsbeek A, Wezel M, Visser I, Ruhé HG, Franceschi C, Garagnani P, Pirazzini C, Capri M, Dall'Olio F, Chiricolo M, Salvioli S, Hoeijmakers J, Pothof J, Prins M, Martens M, Moll S, Berkel J, Totté M, Kovalev S, Gisslén M, Fuchs D, Zetterberg H, Winston A, Underwood J, McDonald L, Stott M, Legg K, Lovell A, Erlwein O, Doyle N, Kingsley C, Sharp DJ, Leech R, Cole JH, Zaheri S, Hillebregt MMJ, Ruijs YMC, Benschop DP, Burger D, de Graaff-Teulen M, Guaraldi G, Bürkle A, Sindlinger T, Moreno-Villanueva M, Keller A, Sabin C, de Francesco D, Libert C, Dewaele S, Boffito M, Mallon P, Post F, Sabin C, Sachikonye M, Winston A, Anderson J, Asboe D, Boffito M, Garvey L, Mallon P, Post F, Pozniak A, Sabin C, Sachikonye M, Vera J, Williams I, Winston A, Post F, Campbell L, Yurdakul S, Okumu S, Pollard L, Williams I, Otiko D, Phillips L, Laverick R, Fisher M, Clarke A, Vera J, Bexley A, Richardson C, Mallon P, Macken A, Ghavani-Kia B, Maher J, Byrne M, Flaherty A, Anderson J, Mguni S, Clark R, Nevin-Dolan R, Pelluri S, Johnson M, Ngwu N, Hemat N, Jones M, Carroll A, Whitehouse A, Burgess L, Babalis D, Winston A, Garvey L, Underwood J, Stott M, McDonald L, Boffito M, Asboe D, Pozniak A, Higgs C, Seah E, Fletcher S, Anthonipillai M, Moyes A, Deats K, Syed I, Matthews C., Molecular Genetics, Biomedical Engineering and Physics, Radiology and Nuclear Medicine, ACS - Atherosclerosis & ischemic syndromes, ACS - Diabetes & metabolism, ACS - Microcirculation, AMS - Restoration & Development, Amsterdam Neuroscience - Brain Imaging, Amsterdam Neuroscience - Neurovascular Disorders, Graduate School, AII - Infectious diseases, APH - Aging & Later Life, Medical Psychology, Amsterdam Neuroscience - Neurodegeneration, Global Health, Infectious diseases, APH - Mental Health, APH - Methodology, Commission of the European Communities, Imperial College Healthcare NHS Trust- BRC Funding, and National Institute for Health Research
- Subjects
Multivariate statistics ,medicine.medical_specialty ,COmorBidity in Relation to AIDS (COBRA) Collaboration and the Pharmacokinetic and clinical Observations in PePle over fiftY (POPPY) Study Group ,Immunology ,Human immunodeficiency virus (HIV) ,Audiology ,medicine.disease_cause ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,multivariate ,SDG 3 - Good Health and Well-being ,Neuroimaging ,Medicine and Health Sciences ,medicine ,Major Article ,OLDER-PEOPLE ,030212 general & internal medicine ,VALIDITY ,Cognitive impairment ,cognitive impairment ,Science & Technology ,neuroimaging ,SCORES ,business.industry ,Biology and Life Sciences ,HIV ,MEN ,Cognition ,Mental health ,White matter microstructure ,PREVALENCE ,3. Good health ,Infectious Diseases ,Oncology ,REGISTRATION ,business ,Life Sciences & Biomedicine ,Neurocognitive ,030217 neurology & neurosurgery - Abstract
Background The optimum method of defining cognitive impairment in virally suppressed people living with HIV is unknown. We evaluated the relationships between cognitive impairment, including using a novel multivariate method (NMM), patient– reported outcome measures (PROMs), and neuroimaging markers of brain structure across 3 cohorts. Methods Differences in the prevalence of cognitive impairment, PROMs, and neuroimaging data from the COBRA, CHARTER, and POPPY cohorts (total n = 908) were determined between HIV-positive participants with and without cognitive impairment defined using the HIV-associated neurocognitive disorders (HAND), global deficit score (GDS), and NMM criteria. Results The prevalence of cognitive impairment varied by up to 27% between methods used to define impairment (eg, 48% for HAND vs 21% for NMM in the CHARTER study). Associations between objective cognitive impairment and subjective cognitive complaints generally were weak. Physical and mental health summary scores (SF-36) were lowest for NMM-defined impairment (P < .05). There were no differences in brain volumes or cortical thickness between participants with and without cognitive impairment defined using the HAND and GDS measures. In contrast, those identified with cognitive impairment by the NMM had reduced mean cortical thickness in both hemispheres (P < .05), as well as smaller brain volumes (P < .01). The associations with measures of white matter microstructure and brain-predicted age generally were weaker. Conclusion Different methods of defining cognitive impairment identify different people with varying symptomatology and measures of brain injury. Overall, NMM-defined impairment was associated with most neuroimaging abnormalities and poorer self-reported health status. This may be due to the statistical advantage of using a multivariate approach., We have previously described a novel multivariate method (NMM) with theoretical statistical advantages over existing methods, which we assessed here in 3 cohorts of people living with HIV. Overall, NMM-defined impairment was associated with most neuroimaging abnormalities and poorer self-reported health status.
- Published
- 2019
3. The ‘COmorBidity in Relation to AIDS’ (COBRA) cohort: Design, methods and participant characteristics
- Author
-
De Francesco, Davide, Wit, Ferdinand W., Cole, James H., Kootstra, Neeltje A., Winston, Alan, Sabin, Caroline A., Underwood, Jonathan, van Zoest, Rosan A., Schouten, Judith, Kooij, Katherine W., Prins, Maria, Guaraldi, Giovanni, Caan, Matthan W. A., Burger, David, Franceschi, Claudio, Libert, Claude, Bürkle, Alexander, Reiss, Peter, APH - Aging & Later Life, AII - Infectious diseases, Global Health, Experimental Immunology, Graduate School, AII - Amsterdam institute for Infection and Immunity, Infectious diseases, APH - Global Health, Biomedical Engineering and Physics, ACS - Atherosclerosis & ischemic syndromes, ANS - Brain Imaging, Radiology and Nuclear Medicine, APH - Methodology, ACS - Diabetes & metabolism, and ACS - Microcirculation
- Subjects
RNA viruses ,Male ,Comorbidity ,Pathology and Laboratory Medicine ,Biochemistry ,DISEASE ,Cohort Studies ,ANTIRETROVIRAL THERAPY ,Immunodeficiency Viruses ,immune system diseases ,Biochemistry, Genetics and Molecular Biology (all) ,Agricultural and Biological Sciences (all) ,Medicine and Health Sciences ,LIFE EXPECTANCY ,Longitudinal Studies ,Netherlands ,Cognitive Impairment ,Anthropometry ,Cognitive Neurology ,virus diseases ,HIV diagnosis and management ,Middle Aged ,Neurology ,Medical Microbiology ,Research Design ,Behavioral Pharmacology ,Viral Pathogens ,Viruses ,Female ,Pathogens ,Anatomy ,Research Article ,Anti-HIV Agents ,Cognitive Neuroscience ,Men WHO Have Sex with Men ,DIAGNOSIS ,Research and Analysis Methods ,Microbiology ,MORBIDITY ,HIV-INFECTION ,PEOPLE ,ddc:570 ,Recreational Drug Use ,mental disorders ,Retroviruses ,Humans ,Noncommunicable Diseases ,Microbial Pathogens ,Pharmacology ,Acquired Immunodeficiency Syndrome ,MORTALITY ,Lentivirus ,Organisms ,Biology and Life Sciences ,HIV ,PREVENTION ,Diagnostic medicine ,United Kingdom ,nervous system ,Socioeconomic Factors ,People and Places ,Cognitive Science ,Population Groupings ,Biomarkers ,Sexuality Groupings ,Neuroscience ,Follow-Up Studies - Abstract
Background : Persons living with HIV on combination antiretroviral therapy (cART) may be at increased risk of the development of age-associated non-communicable comorbidities (AANCC) at relatively young age. It has therefore been hypothesised that such individuals, despite effective cART, may be prone to accelerated aging. Objective : The COmorBidity in Relation to AIDS (COBRA) cohort study was designed to investigate the potential causal link between HIV and AANCC, amongst others, in a cohort of middle-aged individuals with HIV with sustained viral suppression on cART and otherwise comparable HIV-negative controls. Methods : Longitudinal cohort study of HIV-positive subjects >= 45 years of age, with sustained HIV suppression on cART recruited from two large European HIV treatment centres and similarly-aged HIV-negative controls recruited from sexual health centres and targeted community groups. Both HIV-positive and HIV-negative subjects were assessed at study entry and again at follow-up after 2 years. Results : Of the 134 HIV-positive individuals with a median (IQR) age of 56 (51, 62) years recruited, 93% were male, 88% of white ethnicity and 86% were men who have sex with men (MSM). Similarly, the 79 HIV-negative subjects had a median (IQR) age of 57 (52, 64) and 92% were male, 97% of white ethnicity and 80% were MSM. Conclusions : The results from the COBRA study will be a significant resource to understand the link between HIV and AANCC and the pathogenic mechanisms underlying this link. COBRA will inform future development of novel prognostic tools for earlier diagnosis of AANCC and of novel interventions which, as an adjunct to cART, may prevent AANCC.
- Published
- 2018
4. No evidence for accelerated ageing-related brain pathology in treated HIV: longitudinal neuroimaging results from the Comorbidity in Relation to AIDS (COBRA) project
- Author
-
Cole, James H., Caan, Matthan W. A., Underwood, Jonathan, de Francesco, Davide, van Zoest, Rosan A., Wit, Ferdinand W. N. M., Mutsaerts, Henk J. M. M., Leech, Rob, Geurtsen, Gert J., Portegies, Peter, Majoie, Charles B. L. M., Schim van der Loeff, Maarten F., Sabin, Caroline A., Reiss, Peter, Winston, Alan, Sharp, David J., Commission of the European Communities, National Institute for Health Research, Radiology and Nuclear Medicine, AII - Infectious diseases, APH - Aging & Later Life, Graduate School, Global Health, APH - Mental Health, Medical Psychology, AII - Amsterdam institute for Infection and Immunity, Other departments, ACS - Amsterdam Cardiovascular Sciences, Infectious diseases, ANS - Neuroinfection & -inflammation, APH - Methodology, ACS - Microcirculation, ACS - Atherosclerosis & ischemic syndromes, and ACS - Diabetes & metabolism
- Subjects
Science & Technology ,neuroimaging ,COBRA collaboration ,brain structure ,Immunology ,aging ,NEURODEGENERATION ,HIV ,MEN ,11 Medical And Health Sciences ,06 Biological Sciences ,Microbiology ,DISEASE ,ATROPHY ,Infectious Diseases ,AGE ,HIV-INFECTION ,CEREBRAL-BLOOD-FLOW ,RISK-FACTORS ,INJURY ,COMBINATION ANTIRETROVIRAL THERAPY ,Life Sciences & Biomedicine ,cognitive function - Abstract
Background Despite successful antiretroviral therapy people living with HIV (PLWH) experience higher rates of age-related morbidity, including abnormal brain structure, brain function and cognitive impairment. This has raised concerns that PLWH may experience accelerated ageing-related brain pathology. Methods We performed a multi-centre longitudinal study of 134 virologically-suppressed PLWH (median age = 56.0 years) and 79 demographically-similar HIV-negative controls (median age = 57.2 years). To measure cognitive performance and brain pathology, we conducted detailed neuropsychological assessments and multi-modality neuroimaging (T1-weighted, T2-weighted, diffusion-MRI, resting-state functional-MRI, spectroscopy, arterial spin labelling) at baseline and after two-year follow-up. Group differences in rates of change were assessed using linear mixed effects models. Results 123 PLWH and 78 HIV-negative controls completed longitudinal assessments (median interval = 1.97 years). There were no differences between PLWH and HIV-negative controls in age, sex, years of education, smoking, alcohol use, recreational drug use, blood pressure, body-mass index or cholesterol levels. At baseline, PLWH had poorer global cognitive performance (P0.1). Cognitive performance was stable across the study period in both groups. Conclusions Our finding indicate that when receiving successful treatment, middle-aged PLWH are not at increased risk of accelerated ageing-related brain changes or cognitive decline over two years, when compared to closely-matched HIV-negative controls.
- Published
- 2017
5. No Evidence for Accelerated Aging-Related Brain Pathology in Treated Human Immunodeficiency Virus: Longitudinal Neuroimaging Results From the Comorbidity in Relation to AIDS (COBRA) Project.
- Author
-
Cole, James H, Caan, Matthan W A, Underwood, Jonathan, Francesco, Davide De, Zoest, Rosan A van, Wit, Ferdinand W N M, Mutsaerts, Henk J M M, Leech, Rob, Geurtsen, Gert J, and Portegies, Peter
- Subjects
- *
DIAGNOSIS of brain diseases , *HIV infections , *THERAPEUTICS , *AGING , *COGNITION , *LONGITUDINAL method , *MAGNETIC resonance imaging , *NEUROPSYCHOLOGICAL tests , *MEDICAL cooperation , *NEURORADIOLOGY , *REGRESSION analysis , *RESEARCH , *SPECTRUM analysis , *COMORBIDITY , *GRAY matter (Nerve tissue) - Abstract
Background. Despite successful antiretroviral therapy, people living with human immunodeficiency virus (PLWH) experience higher rates of age-related morbidity, including abnormal brain structure, brain function, and cognitive impairment. This has raised concerns that PLWH may experience accelerated aging-related brain pathology. Methods. We performed a multicenter longitudinal study of 134 virologically suppressed PLWH (median age, 56.0 years) and 79 demographically similar human immunodeficiency virus (HlV)-negative controls (median age, 57.2 years). To measure cognitive performance and brain pathology, we conducted detailed neuropsychological assessments and multimodality neuroimaging (T1-weighted, T2-weighted, diffusion magnetic resonance imaging [MRI], resting-state functional MRI, spectroscopy, arterial spin labeling) at baseline and at 2 years. Group differences in rates of change were assessed using linear mixed effects models. Results. One hundred twenty-three PLWH and 78 HIV-negative controls completed longitudinal assessments (median interval, 1.97 years). There were no differences between PLWH and HIV-negative controls in age, sex, years of education, smoking or alcohol use. At baseline, PLWH had poorer global cognitive performance (P < .01), lower gray matter volume (P = .04), higher white matter hyperintensity load (P = .02), abnormal white matter microstructure (P < .005), and greater brain-predicted age difference (P = .01). Longitudinally, there were no significant differences in rates of change in any neuroimaging measure between PLWH and HIV-negative controls (P > .1). Cognitive performance was longitudinally stable in both groups. Conclusions. We found no evidence that middle-aged PLWH, when receiving successful treatment, are at increased risk of accelerated aging-related brain changes or cognitive decline over 2 years. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers.
- Author
-
van Zoest, Rosan A., Underwood, Jonathan, De Francesco, Davide, Sabin, Caroline A., Cole, James H., Wit, Ferdinand W., Caan, Matthan W. A., Kootstra, Neeltje A., Fuchs, Dietmar, Zetterberg, Henrik, Majoie, Charles B. L. M., Portegies, Peter, Winston, Alan, Sharp, David J., Gisslén, Magnus, Reiss, Peter, and Comorbidity in Relation to AIDS (COBRA) Collaboration
- Subjects
BRAIN abnormalities ,HIV infections ,THERAPEUTICS ,CEREBROSPINAL fluid ,BIOMARKERS ,BRAIN imaging ,HYPERTENSION ,BRAIN ,COMPARATIVE studies ,HIV ,RESEARCH methodology ,MEDICAL cooperation ,NEURORADIOLOGY ,QUESTIONNAIRES ,RESEARCH ,RESEARCH funding ,ANTIRETROVIRAL agents ,EVALUATION research ,HIGHLY active antiretroviral therapy - Abstract
Background: Brain structural abnormalities have been reported in persons living with human immunodeficiency virus (HIV; PLWH) who are receiving suppressive combination antiretroviral therapy (cART), but their pathophysiology remains unclear.Methods: We investigated factors associated with brain tissue volumes and white matter microstructure (fractional anisotropy) in 134 PLWH receiving suppressive cART and 79 comparable HIV-negative controls, aged ≥45 years, from the Comorbidity in Relation to AIDS cohort, using multimodal neuroimaging and cerebrospinal fluid biomarkers.Results: Compared with controls, PLWH had lower gray matter volumes (-13.7 mL; 95% confidence interval, -25.1 to -2.2) and fractional anisotropy (-0.0073; 95% confidence interval, -.012 to -.0024), with the largest differences observed in those with prior clinical AIDS. Hypertension and the soluble CD14 concentration in cerebrospinal fluid were associated with lower fractional anisotropy. These associations were independent of HIV serostatus (Pinteraction = .32 and Pinteraction = .59, respectively) and did not explain the greater abnormalities in brain structure in relation to HIV infection.Conclusions: The presence of lower gray matter volumes and more white matter microstructural abnormalities in well-treated PLWH partly reflect a combination of historical effects of AIDS, as well as the more general influence of systemic factors, such as hypertension and ongoing neuroinflammation. Additional mechanisms explaining the accentuation of brain structure abnormalities in treated HIV infection remain to be identified. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.